MNMD vs. USNA, ACB, BTMD, CDXC, CRON, MDWD, CGC, YMAB, IRON, and ANAB
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include USANA Health Sciences (USNA), Aurora Cannabis (ACB), biote (BTMD), ChromaDex (CDXC), Cronos Group (CRON), MediWound (MDWD), Canopy Growth (CGC), Y-mAbs Therapeutics (YMAB), Disc Medicine (IRON), and AnaptysBio (ANAB). These companies are all part of the "medical" sector.
Mind Medicine (MindMed) (NASDAQ:MNMD) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
In the previous week, USANA Health Sciences had 21 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 26 mentions for USANA Health Sciences and 5 mentions for Mind Medicine (MindMed). Mind Medicine (MindMed)'s average media sentiment score of 0.39 beat USANA Health Sciences' score of 0.34 indicating that Mind Medicine (MindMed) is being referred to more favorably in the media.
Mind Medicine (MindMed) presently has a consensus target price of $25.20, indicating a potential upside of 166.67%. USANA Health Sciences has a consensus target price of $46.00, indicating a potential upside of 2.31%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, equities analysts clearly believe Mind Medicine (MindMed) is more favorable than USANA Health Sciences.
USANA Health Sciences received 361 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 89.47% of users gave Mind Medicine (MindMed) an outperform vote while only 60.68% of users gave USANA Health Sciences an outperform vote.
27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 2.1% of Mind Medicine (MindMed) shares are owned by company insiders. Comparatively, 0.3% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
USANA Health Sciences has higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Mind Medicine (MindMed) has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
USANA Health Sciences has a net margin of 6.88% compared to Mind Medicine (MindMed)'s net margin of 0.00%. USANA Health Sciences' return on equity of 12.80% beat Mind Medicine (MindMed)'s return on equity.
Summary
USANA Health Sciences beats Mind Medicine (MindMed) on 10 of the 17 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
